103 results
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
been no material adverse change in the capital stock, short-term indebtedness, long-term indebtedness, net current assets or net assets … information is given in the Pricing Prospectus there shall not have been any change in the capital stock or long term debt of the Company or any of its
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
. citizens or long-term residents, “controlled foreign corporations,” “passive foreign investment companies,” corporations that accumulate earnings
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
mark their securities positions to market for U.S. tax purposes, certain former U.S. citizens or long-term residents, “controlled foreign
8-K
EX-10.1
ncwc6l7t49vvp31b3w
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.1
4vjm2tkx
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.2
bezv1ps4ttvu53vian
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-1.1
yduo7tp
13 Sep 22
Other Events
9:55pm
424B5
nl3bkvgc5yg4yz7ni
13 Sep 22
Prospectus supplement for primary offering
9:13pm
424B5
pqzb7vce5 lvyzk
12 Sep 22
Prospectus supplement for primary offering
4:09pm